Core Viewpoint - The termination of the 7.6 billion yuan acquisition of Shiyao Baike Biotech by XinNuoWei highlights significant operational challenges, including declining performance, cash flow issues, and excessive R&D expenditures, pushing the company towards a critical transformation juncture [1][5]. Group 1: Acquisition and Market Challenges - The acquisition of Shiyao Baike Biotech was officially halted by the Shenzhen Stock Exchange after 15 months of planning, marking a significant setback for XinNuoWei [1]. - The core product of Shiyao Baike, the long-acting G-CSF drug "Jin You Li®," saw revenues plummet over 40% year-on-year to 922 million yuan in the first half of 2024, following aggressive price reductions due to provincial alliance procurement [2]. - The competitive landscape for long-acting G-CSF has intensified, evolving from a "six-strong competition" to a "nine-hero melee," with new entrants like Maiwei Biotech posing additional threats [2]. Group 2: Financial Performance and Cash Flow - The company reported a staggering 87.63% drop in net profit attributable to shareholders, falling to 53.72 million yuan in 2024, with a further loss of 26.9 million yuan in the first quarter of 2025 [3]. - R&D expenses surged to 240 million yuan in the first quarter of 2024, a 117.68% increase year-on-year, contributing to the company's financial strain [3]. - For the first time, the company experienced negative cash flow, with a net outflow of 1.235 billion yuan from operating activities in 2024, and a continued outflow of 86.79 million yuan in the first quarter of 2025 [3]. Group 3: Transformation and Strategic Pressures - Despite the controlling shareholder, Shiyao Group, increasing its stake by 103 million yuan to bolster market confidence, XinNuoWei continues to face three major pressures: high R&D costs, low cash flow, and weakening traditional business performance [4]. - R&D investments have consumed over 50% of the company's total revenue, raising concerns about the sustainability of this model without rapid commercialization of new products [4]. - The termination of the 7.6 billion yuan acquisition underscores the broader challenges XinNuoWei faces in balancing innovative drug development with declining traditional business segments [5].

证券代码：300765 证券简称：新诺威 公告编号：2025-052 石药创新制药股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 石药创新制药股份有限公司（以下简称"公司"）于 2025 年 3 月 19 日召开第 六届董事会第二十二次会议、第六届监事会第十七次会议，于 2025 年 4 月 15 日 召开 2024 年年度股东大会，会议审议并通过了《关于使用部分闲置募集资金及 自有资金进行现金管理的议案》。在不影响募集资金投资项目建设和公司正常经 营的情况下，公司及子公司使用不超过人民币 8.00 亿元（含本数）额度的闲置募 集资金及不超过人民币 8.00 亿元（含本数）的自有资金进行现金管理，投资安全 性高、流动性好的保本型产品（包括结构性存款、大额存单等），使用期限自股 东大会审议通过之日起 12 个月内有效。在上述额度及决议有效期内，业务可循 环滚动开展。具体内容详见巨潮资讯网（http://www.cninfo.com.cn）披露的《关 于使用部分闲置募集资金及自有资金进行现金管理的公告》 ...

Core Viewpoint - The report highlights the performance and holdings of the Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A, indicating a recent decline in net value but strong returns over various time frames [1]. Fund Performance - The latest net value of the fund is 1.5670 yuan, reflecting a decrease of 1.94% - Over the past month, the fund achieved a return of 3.91%, ranking 171 out of 1959 in its category - In the last three months, the fund's return was 22.33%, ranking 5 out of 1950 - Year-to-date, the fund has returned 30.15%, ranking 17 out of 1943 [1]. Fund Holdings - The top ten stock holdings of the fund account for a total of 64.17%, with the following allocations: - Heng Rui Medicine: 10.23% - Kelun Pharmaceutical: 9.09% - Baile Tianheng: 8.94% - Haizike: 8.27% - Xinlitai: 6.66% - Zai Jian Pharmaceutical-U: 6.10% - Xin Nuo Wei: 4.69% - Rongchang Biotechnology: 3.49% - Nuocheng Jianhua-U: 3.35% - Microelectrophysiology: 3.35% [1]. Fund Background - The Huatai-PineBridge Medical Services Flexible Allocation Mixed Fund A was established on June 18, 2015, and as of March 31, 2025, it has a total scale of 4.408 billion yuan - The fund manager is Zhang Wei, who has extensive experience in the pharmaceutical sector [1][2].

金融界2025年5月26日消息，工银前沿医疗股票A(001717) 最新净值2.9540元，下跌1.86%。该基金近1个 月收益率4.79%，同类排名62|864；近3个月收益率9.08%，同类排名51|853；今年来收益率12.28%，同 类排名93|850。 工银前沿医疗股票A股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、药明康德（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 公开资料显示，工银前沿医疗股票A基金成立于2016年2月3日，截至2025年3月31日，工银前沿医疗股 票A规模90.81亿元，基金经理为赵蓓。 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2016年2月 ...

Core Viewpoint - The article discusses the performance and holdings of the Industrial and Commercial Bank of China Medical Healthcare Stock Fund, highlighting its recent net value, returns, and top holdings [1]. Fund Performance - The latest net value of the ICBC Medical Healthcare Stock Fund is 2.5580 yuan, reflecting a decrease of 1.16% - The fund's return over the past month is 3.52%, ranking 172 out of 940 in its category - Over the last six months, the return is 9.79%, with a ranking of 202 out of 914 - Year-to-date, the return stands at 12.24%, ranking 98 out of 926 [1]. Fund Holdings - The top ten holdings of the ICBC Medical Healthcare Stock Fund account for a total of 39.79%, with the following key positions: - Heng Rui Medicine: 8.90% - WuXi AppTec: 5.12% - Aier Eye Hospital: 4.94% - BeiGene: 3.77% - Zai Lab: 3.52% - New Horizon Health: 3.27% - Mindray Medical: 2.80% - Yuwell Medical: 2.76% - United Imaging Healthcare: 2.47% - Innovent Biologics: 2.24% [1]. Fund Management - The ICBC Medical Healthcare Stock Fund was established on November 18, 2014, and as of March 31, 2025, it has a total scale of 2.724 billion yuan - The fund is managed by Zhao Bei and Ding Yang, both of whom have extensive experience in the healthcare sector [1][2].

Core Viewpoint - The termination of the merger between New Nuo Wei and Shiyao Baike Bio marks a significant setback for New Nuo Wei's innovative drug strategy, leading to a financial crisis due to high R&D costs and declining cash flow [2][10]. Financial Performance - New Nuo Wei's net profit for 2024 was 53.73 million yuan, a decrease of 87.63% year-on-year, and in Q1 2025, the net profit loss was 26.90 million yuan, a decline of 134.03% [10]. - The company's operating cash flow for 2024 was -1.235 billion yuan, marking its first instance of cash flow loss, with Q1 2025 still showing a negative cash flow of -86.80 million yuan [10][11]. - The total revenue for New Nuo Wei in Q1 2025 was 472 million yuan, a year-on-year decrease of 9.94%, while the total revenue for 2024 was 1.981 billion yuan, down 21.98% [15]. Product Performance - The core product "Jin You Li" (long-acting G-CSF drug) saw a dramatic revenue decline, with projected 2024 revenue of 922 million yuan, down from 2.316 billion yuan in 2023 [3][4]. - The average selling price of "Jin You Li" dropped from 1,349.22 yuan per unit in 2022 to 1,053.12 yuan per unit by mid-2024 [4][5]. - Sales volume for "Jin You Li" in the first half of 2024 was 87.39 million units, compared to 203.52 million units in 2023 [5]. Market Competition - The market for long-acting G-CSF drugs has intensified, with New Nuo Wei's "Jin You Li" facing competition from multiple new entrants, increasing the competitive landscape from six to nine major players [4][6]. - The reliance on a single product for revenue generation poses a significant risk, as "Jin You Li" accounted for over 97% of Shiyao Baike's income [3][6]. Strategic Implications - The failed merger was intended to provide stable income and cash flow to support New Nuo Wei's R&D investments in its subsidiary, Jushi Bio, which is currently under financial strain [10]. - The ongoing high R&D expenditures have significantly impacted New Nuo Wei's profitability, with a gross margin of 41.97% in 2024, down 3.36 percentage points year-on-year [15].

金融界5月23日消息，上证指数低开低走，中证万得重组主题指数 (CSWD重组，930640)下跌1.17%，报 1567.53点，成交额404.53亿元。 数据统计显示，中证万得重组主题指数近一个月上涨3.77%，近三个月下跌4.89%，年至今下跌5.54%。 从中证万得重组主题指数持仓的市场板块来看，深圳证券交易所占比57.05%、上海证券交易所占比 42.66%、北京证券交易所占比0.29%。 从中证万得重组主题指数持仓样本的行业来看，信息技术占比30.18%、工业占比28.50%、可选消费占 比9.86%、金融占比7.69%、原材料占比7.41%、通信服务占比6.02%、主要消费占比3.31%、房地产占比 2.36%、医药卫生占比2.18%、公用事业占比1.98%、能源占比0.50%。 资料显示，指数样本每月调整一次，样本调整实施时间为每月第一个交易日。权重因子随样本定期调整 而调整，调整时间与指数样本定期调整实施时间相同。在下一个定期调整日前，权重因子一般固定不 变。特殊情况下将对指数进行临时调整。当样本退市时，将其从指数样本中剔除。样本公司发生收购、 合并、分拆等情形的处理，参照计算与维护细则处理。 ...

证券代码：300765 证券简称：新诺威 公告编号：2025-051 石药创新制药股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 股份 12,000,225 股不参与本次权益分派。公司 2024 年年度权益分派方案为：以 公司现有总股本 1,404,592,944 股剔除公司回购专用证券账户中已回购股份 红利人民币 0.2 元（含税），按"每股现金分红比例不变"的原则，实际派发现金 分红总额=1,392,592,719 股×0.2 元/10 股=27,851,854.38 元（含税）。 算的每 10 股现金红利（含税）=现金分红总额/总股本×10=27,851,854.38 元 /1,404,592,944 股×10=0.198291 元。 -按公司总股本折算每股现金分红比例）=（除权除息前一交易日收盘价-0.0198291 元/股）。 一、股东大会审议通过利润分配及资本公积金转增股本方案的情况 年年度股东大会审议通过。公司利润分配方案为：以公司现有总股本 本 1,392,592,719 股为基数，向全体股东以每 10 股派发现金红利 ...

2、本次权益分派实施后计算除权除息价格时，按总股本（含回购股份）折 算的每 10 股现金红利（含税）=现金分红总额/总股本×10=27,851,854.38 元 /1,404,592,944 股×10=0.198291 元。 证券代码：300765 证券简称：新诺威 公告编号：2025-051 石药创新制药股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、石药创新制药股份有限公司（以下简称"公司"）回购专用证券账户中的 股份 12,000,225 股不参与本次权益分派。公司 2024 年年度权益分派方案为：以 公司现有总股本 1,404,592,944 股剔除公司回购专用证券账户中已回购股份 12,000,225 股后的股本 1,392,592,719 股为基数，向全体股东以每 10 股派发现金 红利人民币 0.2 元（含税），按"每股现金分红比例不变"的原则，实际派发现金 分红总额=1,392,592,719 股×0.2 元/10 股=27,851,854.38 元（含税）。 3、本次权益分派实施 ...

公开资料显示，工银前沿医疗股票C基金成立于2020年11月23日，截至2025年3月31日，工银前沿医疗 股票C规模13.80亿元，基金经理为赵蓓。 金融界2025年5月21日消息，工银前沿医疗股票C(010685) 最新净值2.9140元，增长1.53%。该基金近1个 月收益率4.11%，同类排名420|1001；近3个月收益率9.30%，同类排名81|988；今年来收益率13.47%， 同类排名116|978。 工银前沿医疗股票C股票持仓前十占比合计59.05%，分别为：恒瑞医药（10.11%）、科伦药业 （8.01%）、XD药明康（7.72%）、百济神州-U（6.85%）、信立泰（4.90%）、泽璟制药-U （4.77%）、鱼跃医疗（4.60%）、新诺威（4.36%）、华东医药（4.20%）、海思科（3.53%）。 来源：金融界 简历显示：赵蓓女士:硕士,曾在中再资产管理股份有限公司担任投资经理助理。2010年加入工银瑞信,现 任研究部副总监、医疗保健研究团队负责人,2014年11月18日至今,担任工银医疗保健行业股票型基金基 金经理;2015年4月28日至今,担任工银瑞信养老产业股票型基金基金经理;2 ...